CBD gummies in Australia

CBD gummies cannot be lawfully bought without a prescription in Australia. The law, what trials say about edible CBD, and the risks of unregulated products.

Facts checked 13 November 20268 min readHow we research

You cannot lawfully buy CBD gummies without a prescription in Australia. CBD is a prescription medicine here, no gummy has been approved for over-the-counter sale, and food law does not allow CBD to be added to confectionery. A chewable cannabis medicine can be prescribed, but the regulator says the evidence for edible forms is limited. This page does not list or rank products. It explains the law, the science and the risks.

There are four situations, and the answer differs for each. This is the position as of November 2026.

1. Sold as a medicine without a prescription: not lawful. CBD for therapeutic use is a Schedule 4 (prescription only) medicine.1 A pharmacist-only (Schedule 3) category exists for low-dose oral CBD, but only for a product on the Australian Register of Therapeutic Goods. The TGA said in August 2025 that no complete application for such a product had been submitted or evaluated, and that no cannabis medicine had been registered through that route.2 See over-the-counter CBD.

2. Prescribed as an unapproved medicine: possible. When a prescriber applies to supply an unapproved cannabis medicine, the TGA’s system offers 19 dosage forms. They include “pastille”, “lozenge” and “tablet, chewable”.2 So a chewable cannabis medicine can be lawfully prescribed and dispensed by a pharmacy. It is still an unapproved product, which the TGA says has “not been assessed by us for safety, quality or effectiveness”.3 One analysis of TGA data reported that edibles made up 19.7% of Special Access Scheme approvals for all cannabis medicines in the year to October 2025. That figure covers products with THC, not CBD alone.4

3. Sold as a food or lolly: not lawful. Only hemp seeds and seed products are permitted as food. The Food Standards Code says cannabidiol “must not be present in any food for sale at a level greater than 75 mg/kg”, and labels cannot make a nutrition or health claim about CBD.5 A 5 gram gummy at that limit would hold less than 0.4 mg of CBD. Products sold in Australia as “hemp gummies” are therefore either hemp seed foods with next to no CBD, or they are outside the food rules. See hemp foods.

4. Ordered from an overseas website: not lawful. The TGA says cannabis products are excluded from personal importation, apart from the traveller’s exemption.6 In 2021 the Australian Border Force warned, after “a marked increase” in interceptions of “hemp or CBD gummies, oils and skin care products”, that such items will be seized and importers may face prosecution.7 See buying CBD online and importing CBD.

What does the TGA say about edible forms?

In its 2025 review of unapproved cannabis medicines, the TGA wrote that there is “limited evidence to support the safety and efficacy of other dosage forms such as sprays, suppositories, topicals and edibles”. It also noted that no ongoing clinical assessment is made of the risks each dosage form may present. The form is chosen by the prescriber.2

The Department of Veterans’ Affairs has gone further for the treatment it funds. It pays only for capsules and liquids among the oral forms, not “edibles like pastilles or gummies”, to “reduce the risk of harm from accidental ingestion of edible medicinal cannabis products by children and animals”.8

As of November 2026, no change to the general law on gummies had been announced in the latest TGA documents we could find. See how the TGA regulates CBD.

How well is CBD absorbed from a gummy?

A gummy is chewed and swallowed, so the CBD is absorbed through the gut like a capsule or swallowed oil. What is known about swallowed CBD applies:

  • Little gets through on an empty stomach. About 6% of a swallowed dose reaches the bloodstream when fasting, and the amount is erratic.9
  • Food changes it several-fold. A high-fat meal raised peak blood levels of CBD oil about five times and total exposure about four times.10
  • It is slow. Blood levels after a swallowed dose peak in roughly one to four hours.11

We did not find a study that measured the absolute absorption of CBD from a gummy. A systematic review of human studies found that inhaling was the only route, other than swallowing, with a properly measured figure.12 Claims that a gummy has a known or superior “bioavailability” should be read with that in mind. See ways to take CBD compared.

What do trials say about edible CBD?

Very few trials have used an edible form. One crossover trial gave 32 women with irritable bowel syndrome a chewing gum containing 50 mg of CBD, to use as needed. It found no significant difference in pain compared with a placebo gum.13

More broadly, dose matters more than format. Australian researchers writing in Australian Prescriber noted that very low doses of CBD (about 5 to 25 mg) have little evidence of health benefit.14 A later review by the same group of oral CBD at doses up to 400 mg a day found that benefits became more clearly evident at 300 mg a day or more.15 A trial of 20 to 30 mg a day for arthritis pain, and a trial of 150 mg a night for insomnia, found CBD similar to placebo on their main measures.1617 See does low-dose CBD work?

What are the risks of unregulated gummies?

The label may be wrong. A 2024 study tested 202 CBD products bought online in the United States, including 48 gummies. Of the gummies, 27 contained less than 90% of the labelled CBD, 17 were within 10% of the label and 4 contained more than 110%. Gummies were more likely than tinctures (oils), topicals or vape products to fall short. Among products labelled “full spectrum”, gummies and vapes were less likely than tinctures or topicals to match that claim.18

There may be contaminants. In the same study, lead was the only heavy metal found above regulatory thresholds. It exceeded them in five products, one of which was a gummy. Residual solvents were detected in 181 of the 202 products.18

There may be THC. In another United States study, 5 of 21 products labelled “THC-free” contained measurable THC.19 THC in a product marketed as CBD can lead to a positive drug test and, in a child, to poisoning. See CBD and drug tests.

They look like lollies. The serious child poisonings from cannabis edibles described in the medical literature involve THC, including its close relative delta-8-THC. In one 2024 report, a seven-year-old who ate five delta-8-THC gummies had a pause in heartbeat and breathing seven hours later and needed intensive care observation.20 Pure CBD was not the cause, but a mislabelled or THC-containing gummy carries this risk. See CBD for children and teenagers.

Pets are at risk too. THC is toxic to dogs.21 See pet safety.

By contrast, prescription products supplied in Australia must meet a quality standard that sets content limits, contaminant limits and child-resistant packaging.22 See is what is on the label in the bottle?

If you are considering a chewable CBD product

  • Only a doctor or nurse practitioner can lawfully prescribe a cannabis medicine, and whether any CBD product suits a person is their decision. See how CBD prescribing works in Australia.
  • Ask the prescriber why a chewable form would be chosen over an oil or capsule, and whether the product contains THC.
  • Store any cannabis medicine in its child-resistant pack, out of sight and reach of children and pets. See storing CBD.
  • CBD has side effects and interacts with other medicines, whatever shape it comes in. See CBD side effects and CBD drug interactions.

Footnotes

  1. Australian Government. Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026, Schedule 3 and Schedule 4 cannabidiol entries. https://www.legislation.gov.au/F2026L01327/asmade/2026-09-30/text/original/pdf ↩

  2. Therapeutic Goods Administration. Consultation: Reviewing the safety and regulatory oversight of unapproved medicinal cannabis products, version 1.0, August 2025. https://consultations.tga.gov.au/medicines-regulation-division/test-soms/user_uploads/final---consultation-paper---medicinal-cannabis-review---august-2025.pdf ↩ ↩2 ↩3

  3. Therapeutic Goods Administration. Access pathways for medicinal cannabis. https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis/access-pathways ↩

  4. Penington Institute. Cannabis in Australia, November 2025. https://www.penington.org.au/wp-content/uploads/2025/11/Penington_Institute_Cannabis-in-Australia_Nov_2025.pdf ↩

  5. Food Standards Australia New Zealand. Australia New Zealand Food Standards Code, Standard 1.4.4, Prohibited and restricted plants and fungi (compilation of 12 November 2017). https://www.legislation.gov.au/F2015L00416/2017-11-12/2017-11-12/text/original/epub/OEBPS/document_1/document_1.html ↩

  6. Therapeutic Goods Administration. Medicinal cannabis: importation and the traveller’s exemption. https://www.tga.gov.au/resources/explore-topic/medicinal-cannabis-hub/medicinal-cannabis-information-patients/medicinal-cannabis-importation-and-travellers-exemption ↩

  7. Australian Border Force media release, 5 July 2021, as republished by Mirage News. https://www.miragenews.com/increase-in-seizures-prompts-warning-to-590129/ ↩

  8. Department of Veterans’ Affairs. Updated medicinal cannabis framework supports safe and effective prescribing practices. https://www.dva.gov.au/providers/provider-news/updated-medicinal-cannabis-framework-supports-safe-and-effective-prescribing-practices ↩

  9. World Health Organization, Expert Committee on Drug Dependence. Cannabidiol (CBD) critical review report, 2018. https://cdn.who.int/media/docs/default-source/controlled-substances/whocbdreportmay2018-2.pdf ↩

  10. Therapeutic Goods Administration. Epidyolex (cannabidiol) Australian Product Information, version published with the AusPAR, January 2021 (may have been superseded). https://www.tga.gov.au/sites/default/files/auspar-cannabidiol-210115-pi.pdf ↩

  11. Millar SA, Maguire RF, Yates AS, O’Sullivan SE. Towards better delivery of cannabidiol (CBD). Pharmaceuticals, 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7558665/ ↩

  12. Millar SA, et al. Systematic review of the pharmacokinetics of cannabidiol in humans, 2018. https://pubmed.ncbi.nlm.nih.gov/30534073/ ↩

  13. Crossover randomised trial of cannabidiol chewing gum in irritable bowel syndrome, 2021. https://pubmed.ncbi.nlm.nih.gov/33998882/ ↩

  14. Arnold JC, et al. Review article on cannabidiol. Australian Prescriber, 2020. https://www.nps.org.au/assets/p152-Arnold-et-al.pdf ↩

  15. Arnold JC, McCartney D, Suraev A, McGregor IS. Review of the safety and efficacy of low-dose oral cannabidiol. Clinical and Translational Science, 2023. https://pubmed.ncbi.nlm.nih.gov/36259271/ ↩

  16. Vela J, et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial (conference abstract). https://acrabstracts.org/abstract/cannabidiol-treatment-in-hand-osteoarthritis-and-psoriatic-arthritis-a-randomized-double-blind-placebo-controlled-trial/ ↩

  17. Narayan AJ, et al. Randomised trial of 150 mg cannabidiol nightly for primary insomnia. Journal of Clinical Sleep Medicine, 2024. https://pubmed.ncbi.nlm.nih.gov/38174873/ ↩

  18. Gidal BE, et al. Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Frontiers in Pharmacology, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10982813/ ↩ ↩2

  19. Johnson E, Kilgore M, Babalonis S. Cannabidiol (CBD) product contamination: quantitative analysis of delta-9-THC concentrations found in commercially available CBD products. Drug and Alcohol Dependence, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9899037/ ↩

  20. Masilamani MSJ, Leff R, Kawai Y. Asystole in a young child with tetrahydrocannabinol overdose: a case report and review of literature. Frontiers in Toxicology, 2024. https://www.frontiersin.org/articles/10.3389/ftox.2024.1371651/full ↩

  21. Study of 223 dogs with THC toxicosis. Journal of the American Veterinary Medical Association, 2024. https://pubmed.ncbi.nlm.nih.gov/38608656/ ↩

  22. Australian Government. Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017, compilation of 6 December 2022. https://www.legislation.gov.au/F2017L00286/latest/text ↩

Common questions

Are CBD gummies legal in Australia?

Only on prescription. CBD is a prescription medicine in Australia, no CBD gummy has been approved for sale without a prescription, and the food rules do not allow CBD to be added to food. A chewable cannabis medicine can be prescribed as an unapproved product through the TGA's access pathways.

Can I order CBD gummies online from overseas?

Not lawfully. Cannabis products are excluded from the personal importation scheme, and the Australian Border Force has warned that hemp and CBD gummies will be seized at the border and that importers may face prosecution. Products sold this way are also unregulated, so their contents are uncertain.

Do hemp gummies contain CBD?

A lawful hemp food can contain only a trace. The Food Standards Code caps CBD in any food at 75 mg per kilogram, which works out to less than half a milligram in a 5 gram gummy. Hemp food labels are not allowed to make claims about CBD.

Do CBD gummies work?

No trial has shown that a gummy works differently from any other swallowed CBD. What matters is the dose and the condition. Most trials that reported a benefit from CBD used hundreds of milligrams a day, and Australian researchers have noted that very low doses of about 5 to 25 mg have little evidence of benefit.

This page is general information, not medical or legal advice. Laws and evidence change; we show the date we last checked the facts at the top of every page. Talk to your doctor or pharmacist before starting, stopping or changing any medicine.